Tetrahydrocannabinol: Cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice

European Neurology

Volumn 76, Issue 5-6, 2016, Pages 216-226

  Vermersch, Patrick ^a   Trojano, Maria ^b  

^a UNIV LILLE   (France)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Cannabinoids; Effectiveness; Multiple sclerosis; Spasticity; Tetrahydrocannabinol:cannabidiol oromucosal spray; Tolerability

Indexed keywords

BACLOFEN; CLONAZEPAM; GABAPENTIN; NABIXIMOLS; TIZANIDINE; ORAL SPRAY; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ADVERSE OUTCOME; ANXIETY; APATHY; ARTICLE; ASTHENIA; BACKACHE; BALANCE DISORDER; BLADDER DYSFUNCTION; BRADYPHRENIA; BRAIN DISEASE; BRAIN STEM SYNDROME; CLINICAL PRACTICE; CONFUSION; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DISEASE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; NERVOUSNESS; OBSERVATIONAL STUDY; PAIN; PARESTHESIA; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; PHYSIOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SIDE EFFECT; SLEEP QUALITY; SOMNOLENCE; SPASTICITY; SPEECH DISORDER; SUICIDAL IDEATION; TACHYCARDIA; TREMOR; UNSPECIFIED SIDE EFFECT; WELLBEING; XEROSTOMIA; CLINICAL TRIAL; COMPLICATION; ITALY; MUSCLE SPASTICITY; ORAL SPRAY;

ACTIVITIES OF DAILY LIVING; ADULT; BACLOFEN; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; ORAL SPRAYS; PLANT EXTRACTS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 84991226932     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000449413     Document Type: Article

References (19)

1. Pugliatti M, Rosati G, Carton H, et al: The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700-722
2. Kingwell E, Marriott JJ, Jetté N, et al: Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013; 13: 128
3. Kabus C, Hecht M, Japp G, et al: Botulinum toxin in patients with multiple sclerosis. J Neurol 2006; 253(suppl 1): I26-I28
4. Oreja-Guevara C, González-Segura D, Vila C: Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci 2013; 123: 400-408
5. Bavikatte G, Gaber T: Approach to spasticity in general practice. Br J Med Pract 2009; 2: 29-34
6. Bensmail D, Vermersch P: [Epidemiology and clinical assessment of spasticity in multiple sclerosis]. Rev Neurol (Paris) 2012; 168(suppl 3): S45-S50
7. Arroyo R, Vila C, Dechant KL: Impact of Sativex(® ) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res 2014; 3: 435-444
8. Deutsche Gesellschaft für Neurologie: Diagnose und Therapie der Multiplen Sklerose, Version April 2014. http://www.dgn.org/leitlinien/11-leitlinien-der-dgn/2333-ll-31-2012-diagnose-und-Therapie-der-multiplen-sklerose (last accessed April 2016
9. Shakespeare DT, Boggild M, Young C: Antispasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003; 4: CD001332
10. Collin C, Davies P, Mutiboko IK, Ratcliffe S: Randomized controlled trial of cannabisbased medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-296
11. Collin C, Ehler E, Waberzinek G, et al: A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32: 451-459
12. Novotna A, Mares J, Ratcliffe S, et al: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex( ® )), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122-1131
13. Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X: Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler 2016; pii: 1352458516643600
14. Flachenecker P, Henze T, Zettl UK: Nabiximols (THC/CBD oromucosal spray, Sativex® ) in clinical practice-results of a multicentre, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014; 71: 271-279
15. Trojano M, Vila C: Effectiveness and tolerability of THC/CBD oromucosal spray for multiple sclerosis spasticity in Italy: first data from a large observational study. Eur Neurol 2015; 74: 178-185
16. Sativex Oromucosal Spray: Summary of Product Characteristics (SmPC). www.medicines. org.uk/EMC/medicine/23262/SPC/Sativex+Oromucosal+Spray (last updated May 20, 2015
17. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP: Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 974-985
18. Patti F, Messina S, Solaro C, et al; SA.FE. Study Group: Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry 2016; 87: 944-951
19. Oreja-Guevara C, Casanova B, Ordás CM, Silván CV, Asensio D: Observational safety study of THC: CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity. Clin Exp Pharmacol 2015; 5: 184